Source comparison
PT-141 Dosing: Research vs FDA-Approved Comparison
Standard Dose 1.75mg subcutaneous 0.5mg–2mg subcutaneous Dose-finding studies established 1.75mg as optimal balance between efficacy and tolerability; lower doses used in sensitive populations Maximum Frequency 1 dose per 24 hours, 8 doses per month Varies by
This comparison does not assign a generated winner or score.
- Standard Dose
- 1.75mg subcutaneous
- 0.5mg–2mg subcutaneous
- Dose-finding studies established 1.75mg as optimal balance between efficacy and tolerability; lower doses used in sensitive populations
- Maximum Frequency
- 1 dose per 24 hours, 8 doses per month
- Varies by study design; most mirror FDA label
- Receptor recovery requires 18–24 hours; exceeding 8 doses monthly increases discontinuation without improving outcomes
- Administration Timing
- At least 45 minutes before activity
- 30–90 minutes before desired effect in protocols
- Peak plasma at 30–60 min; CNS effects lag by 15–30 min due to BBB transit time
- Duration of Effect
- 6–12 hours subjective effect
- 6–12 hours (pharmacodynamic window)
- Receptor occupancy persists beyond elimination half-life (2.7 hours) due to slow MC4R dissociation kinetics
- Contraindications
- Uncontrolled hypertension, cardiovascular disease
- Same + pregnancy, breastfeeding
- Transient BP elevation (3–4 mmHg systolic) poses risk in vulnerable populations